EYA2: Potential Drug Target for Eye Diseases (G2139)

Target Name: EYA2

NCBI ID: G2139

EYA2

EYA2: Potential Drug Target for Eye Diseases

Eye-absent homolog 2 (ISOform A), also known as EYA2, is a gene that has been identified in the mouse as a potential drug target for the treatment of various eye diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The gene is located on chromosome 6 and encodes a protein known as EYA2, which is involved in the development and maintenance of the retina.

EYA2 has been shown to play a crucial role in the development and progression of several eye diseases, including cancer. Studies have shown that EYA2 is highly expressed in cancer tissues and that inhibition of the EYA2 gene has been shown to lead to reduced tumor growth and improved survival in animal models of cancer.

In addition to its role in cancer, EYA2 has also been shown to be involved in the development and progression of neurodegenerative diseases. Studies have shown that EYA2 is highly expressed in the brains of individuals with Alzheimer's disease and that inhibition of the EYA2 gene has been shown to lead to reduced neurodegeneration in animal models of Alzheimer's disease.

EYA2 has also been shown to be involved in the development and progression of autoimmune disorders. Studies have shown that EYA2 is highly expressed in the tissues of individuals with rheumatoid arthritis and that inhibition of the EYA2 gene has been shown to reduce the development of autoimmune diseases in animal models.

Despite its potential as a drug target, EYA2 has not yet been approved for use in any clinical trials. However, studies are being conducted to investigate the potential benefits and risks of EYA2-based therapies in these eye diseases.

In conclusion, EYA2 is a gene that has been shown to play a crucial role in the development and progression of several eye diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to investigate the potential benefits and risks of EYA2-based therapies in these diseases.

Protein Name: EYA Transcriptional Coactivator And Phosphatase 2

Functions: Functions both as protein phosphatase and as transcriptional coactivator for SIX1, and probably also for SIX2, SIX4 and SIX5 (PubMed:12500905, PubMed:23435380). Tyrosine phosphatase that dephosphorylates 'Tyr-142' of histone H2AX (H2AXY142ph) and promotes efficient DNA repair via the recruitment of DNA repair complexes containing MDC1. 'Tyr-142' phosphorylation of histone H2AX plays a central role in DNA repair and acts as a mark that distinguishes between apoptotic and repair responses to genotoxic stress (PubMed:19351884). Its function as histone phosphatase may contribute to its function in transcription regulation during organogenesis. Plays an important role in hypaxial muscle development together with SIX1 and DACH2; in this it is functionally redundant with EYA1 (PubMed:12500905)

The "EYA2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EYA2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets